Abstract:Introduction: Rett syndrome (RTT, MIM #312750) is a rare genetic disorder that leads to developmental regression and severe disability and is caused by pathogenic variants in the MECP2 gene. The diagnosis of RTT is based on clinical features and, depending on resources and access, on molecular confirmation. There is scarce information on molecular diagnosis from patients in Latin America, mostly due to limited availability and coverage of genomic testing. This pilot study aimed to implement genomic testing and characterize clinical and molecular findings in a group of Chilean patients with a clinical diagnosis of RTT. Methods: Twenty-eight patients with suspected RTT underwent characterization of phenotypic manifestations and molecular testing using Clinical Exome Solution TM CES_V2 by SOPHiA Genetics. Data was analyzed using the commercial bioinformatics platform, SOPHiA DDM TM . A virtual panel of 34 genes, including MECP2 and other genes that are in the differential diagnosis of RTT, was used to prioritize initial analyses, followed by evaluation of the complete exome sequence data. Results: Twelve patients (42.8% of participants) had variants in MECP2 , of which 11 (39.2%) were interpreted as pathogenic/likely pathogenic (P/LP), thus confirming the diagnosis of RTT in them. Eight additional patients (28.5%) harbored ten variants in nine other genes. Four of these variants were interpreted as P/LP (14.2%) ( GRIN2B, MADD, TRPM3 and ZEB2 ) resulting in alternative neurodevelopmental diagnoses, and six were considered of uncertain significance. No evident candidate variant was found for eight patients. Discussion: This study allowed to reach a diagnosis in half of the participants. The diagnosis of RTT was confirmed in over a third of them, while others were found to have alternative neurodevelopmental disorders. Further evaluation is needed to identify the cause in those with negative or uncertain results. This information is useful for the patients, families, and clinicians to guide clinical management, even more so since the development of novel therapies for RTT. We also show the feasibility of implementing a step-wide approach to genomic testing in a setting with limited resources.

Orthopedic Conditions and Interplay with Functional Abilities and MECP2 Variant Subtype in Rett Syndrome Patients

Prevalence of orthopaedic conditions in Rett syndrome: a systematic review and meta‐analysis

Downregulation of CNPase in a MeCP2 Deficient Mouse Model of Rett Syndrome.

Selective Preservation of Cholinergic Mecp2 Rescues Specific Rett-Syndrome-Like Phenotypes in Mecp2(Stop) Mice

Genetic Instability and Disease Progression of Indian Rett Syndrome Patients

Prevalence of Endocrinopathies in a Cohort of Patients with Rett Syndrome: A two-Center Observational Study

Genomic analysis in Chilean patients with suspected Rett syndrome: keep a broad differential diagnosis

Rett Syndrome and the Role of MECP2: Signaling to Clinical Trials

Global Impairment of Immediate-Early Genes Expression in Rett Syndrome Models and Patients Linked to Myelination Defects

[Correlation Between MECP2 Genotype and Phenotype in Chinese Patients with Rett Syndrome].

MECP2 Mutation Spectrum and Its Clinical Characteristics in a Chinese Cohort

Genetic and Protein Network Underlying the Convergence of Rett-Syndrome-like (RTT-L) Phenotype in Neurodevelopmental Disorders

Clinical Feature of Rett Syndrome and MeCP2 Genotype/phenotype Correlation Analysis

Multimodal Neuroimaging in Rett Syndrome With MECP2 Mutation

MECP2 Gene Mutation Analysis in Chinese Patients with Rett Syndrome

Parental age effects and Rett syndrome

Transcriptome level analysis in Rett syndrome using human samples from different tissues

MECP2 and CDKL5 Gene Mutation Analysis in Chinese Patients with Rett Syndrome

Genotype and Early Development in Rett Syndrome: the Value of International Data.

Rett syndrome in Ireland: a demographic study

Exclusive expression of MeCP2 in the nervous system distinguishes between brain and peripheral Rett syndrome-like phenotypes